24 pending office actions
| App # | Title | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|
| 18740078 | QUINOLINE DERIVATIVES | AULAKH, CHARANJIT | 1621 | Non-Final OA | Jun 11, 2024 |
| 18673168 | ANTIVIRAL COMPOUNDS | LEE, ANDREW P | 1691 | Non-Final OA | May 23, 2024 |
| 18655876 | METHODS OF PREPARING 1'-CYANO NUCLEOSIDES | BERRY, LAYLA D | 1693 | Non-Final OA | May 06, 2024 |
| 18512088 | METHODS FOR TREATING POXVIRUS INFECTIONS | CHAO, ALLEN | 1622 | Non-Final OA | Nov 17, 2023 |
| 18479576 | 4'-THIONUCLEOSIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | OLSON, ANDREA STEFFEL | 1693 | Non-Final OA | Oct 02, 2023 |
| 18469844 | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY | DENT, ALANA HARRIS | 1643 | Non-Final OA | Sep 19, 2023 |
| 18243812 | METHODS FOR TREATMENT OF VIRAL INFECTIONS | LEWIS, PATRICK T | 1691 | Non-Final OA | Sep 08, 2023 |
| 18448721 | DOSING AND SCHEDULING REGIMEN FOR BROADLY NEUTRALIZING ANTIBODIES | GRIZER, CASSANDRA SENN | 1672 | Non-Final OA | Aug 11, 2023 |
| 18264670 | THIENOPYRROLE COMPOUNDS | AULAKH, CHARANJIT | 1621 | Non-Final OA | Aug 08, 2023 |
| 18365919 | SARS-COV2 MAIN PROTEASE INHIBITORS | BORALSKY, LUKE ALAN | 1624 | Non-Final OA | Aug 04, 2023 |
| 18346745 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | FETTEROLF, BRANDON J | 1626 | Non-Final OA | Jul 03, 2023 |
| 18345547 | THERAPEUTIC COMPOUNDS USEFUL FOR THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF AN HIV VIRUS INFECTION | DEKARSKE, MADELINE MCGUIRE | 1622 | Non-Final OA | Jun 30, 2023 |
| 18344560 | CD73 COMPOUNDS | SEITZ, ANTHONY JOSEPH | 1629 | Non-Final OA | Jun 29, 2023 |
| 18215217 | SOLID FORMS OF A NUCLEOSIDE ANALOGUE AND USES THEREOF | SEITZ, ANTHONY JOSEPH | 1629 | Non-Final OA | Jun 28, 2023 |
| 18268469 | 6-SUBSTITUTED INDOLE COMPOUNDS | RAO, PADMAJA S | 1627 | Non-Final OA | Jun 20, 2023 |
| 18268440 | SUBSTITUTED INDOLE COMPOUNDS | REILLY, SOPHIA JANE | 1627 | Final Rejection | Jun 20, 2023 |
| 18313266 | DARUNAVIR COMBINATION FORMULATIONS | LEE, ANDREW P | 1691 | Final Rejection | May 05, 2023 |
| 18303813 | KRAS G12D MODULATING COMPOUNDS | SANCHEZ, JUSTIN CHRISTOPHER | 1622 | Non-Final OA | Apr 20, 2023 |
| 18296296 | ENGINEERED CD200R ANTIBODIES AND USES THEREOF | HOWARD, ZACHARY C | 1674 | Non-Final OA | Apr 05, 2023 |
| 18295163 | COMBINATION THERAPY FOR TREATING COLORECTAL CANCER | TRAN HO, LAM THUY VI | 1647 | Non-Final OA | Apr 03, 2023 |
| 18115895 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | NOTTINGHAM, KYLE GREGORY | 1621 | Non-Final OA | Mar 01, 2023 |
| 18176864 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CHO, DAVID H | 1693 | Non-Final OA | Mar 01, 2023 |
| 17997594 | CD73 COMPOUNDS | NESTOR, DONNA MICHELLE | 1627 | Final Rejection | Oct 31, 2022 |
| 17612426 | DOSAGE REGIMENS FOR VACCINES | JADHAO, SAMADHAN JAISING | 1672 | Non-Final OA | Nov 18, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial